Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans.

Kurtz CB, Millet YA, Puurunen MK, Perreault M, Charbonneau MR, Isabella VM, Kotula JW, Antipov E, Dagon Y, Denney WS, Wagner DA, West KA, Degar AJ, Brennan AM, Miller PF.

Sci Transl Med. 2019 Jan 16;11(475). pii: eaau7975. doi: 10.1126/scitranslmed.aau7975.

PMID:
30651324
2.

Chronic linaclotide treatment reduces colitis-induced neuroplasticity and reverses persistent bladder dysfunction.

Grundy L, Harrington AM, Castro J, Garcia-Caraballo S, Deiteren A, Maddern J, Rychkov GY, Ge P, Peters S, Feil R, Miller P, Ghetti A, Hannig G, Kurtz CB, Silos-Santiago I, Brierley SM.

JCI Insight. 2018 Oct 4;3(19). pii: 121841. doi: 10.1172/jci.insight.121841.

3.

Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria.

Isabella VM, Ha BN, Castillo MJ, Lubkowicz DJ, Rowe SE, Millet YA, Anderson CL, Li N, Fisher AB, West KA, Reeder PJ, Momin MM, Bergeron CG, Guilmain SE, Miller PF, Kurtz CB, Falb D.

Nat Biotechnol. 2018 Oct;36(9):857-864. doi: 10.1038/nbt.4222. Epub 2018 Aug 13.

PMID:
30102294
4.

Demonstration of differences in colonic volumes, transit, chyme consistency, and response to psyllium between healthy and constipated subjects using magnetic resonance imaging.

Major G, Murray K, Singh G, Nowak A, Hoad CL, Marciani L, Silos-Santiago A, Kurtz CB, Johnston JM, Gowland P, Spiller R.

Neurogastroenterol Motil. 2018 Sep;30(9):e13400. doi: 10.1111/nmo.13400. Epub 2018 Jul 30.

PMID:
30062794
5.

Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial.

Schoenfeld P, Lacy BE, Chey WD, Lembo AJ, Kurtz CB, Reasner DS, Bochenek W, Tripp K, Currie MG, Fox SM, Blakesley RE, OʼDea CR, Omniewski ND, Hall ML.

Am J Gastroenterol. 2018 Jan;113(1):105-114. doi: 10.1038/ajg.2017.230. Epub 2017 Aug 22.

6.

Guanylate cyclase 2C agonism corrects CFTR mutants.

Arora K, Huang Y, Mun K, Yarlagadda S, Sundaram N, Kessler MM, Hannig G, Kurtz CB, Silos-Santiago I, Helmrath M, Palermo JJ, Clancy JP, Steinbrecher KA, Naren AP.

JCI Insight. 2017 Oct 5;2(19). pii: 93686. doi: 10.1172/jci.insight.93686.

7.

Linaclotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled Trial.

Lacy BE, Schey R, Shiff SJ, Lavins BJ, Fox SM, Jia XD, Blakesley RE, Hao X, Cronin JA, Currie MG, Kurtz CB, Johnston JM, Lembo AJ.

PLoS One. 2015 Jul 29;10(7):e0134349. doi: 10.1371/journal.pone.0134349. eCollection 2015.

8.

MRP4 Modulation of the Guanylate Cyclase-C/cGMP Pathway: Effects on Linaclotide-Induced Electrolyte Secretion and cGMP Efflux.

Tchernychev B, Ge P, Kessler MM, Solinga RM, Wachtel D, Tobin JV, Thomas SR, Lunte CE, Fretzen A, Hannig G, Bryant AP, Kurtz CB, Currie MG, Silos-Santiago I.

J Pharmacol Exp Ther. 2015 Oct;355(1):48-56. doi: 10.1124/jpet.115.224329. Epub 2015 Jul 27.

PMID:
26216942
9.

Comparison of adequate relief with symptom, global, and responder endpoints in linaclotide phase 3 trials in IBS-C.

Camilleri M, Lembo AJ, Lavins BJ, MacDougall JE, Carson RT, Williams VS, Nelson LM, Shiff SJ, Currie MG, Kurtz CB, Johnston JM.

United European Gastroenterol J. 2015 Feb;3(1):53-62. doi: 10.1177/2050640614555946.

10.

The impact of abdominal pain on global measures in patients with chronic idiopathic constipation, before and after treatment with linaclotide: a pooled analysis of two randomised, double-blind, placebo-controlled, phase 3 trials.

Chang L, Lembo AJ, Lavins BJ, Shiff SJ, Hao X, Chickering JG, Jia XD, Currie MG, Kurtz CB, Johnston JM.

Aliment Pharmacol Ther. 2014 Dec;40(11-12):1302-12. doi: 10.1111/apt.12985. Epub 2014 Oct 13.

11.

Psychometric validation of patient-reported outcome measures assessing chronic constipation.

Nelson LM, Williams VS, Fehnel SE, Carson RT, MacDougall J, Baird MJ, Tourkodimitris S, Kurtz CB, Johnston JM.

Clin Exp Gastroenterol. 2014 Sep 26;7:385-94. doi: 10.2147/CEG.S64713. eCollection 2014.

12.

Assessment of treatment response in chronic constipation clinical trials.

Ervin CM, Fehnel SE, Baird MJ, Carson RT, Johnston JM, Shiff SJ, Kurtz CB, Mangel AW.

Clin Exp Gastroenterol. 2014 Jun 3;7:191-8. doi: 10.2147/CEG.S58321. eCollection 2014.

13.

Guanylate cyclase-C/cGMP: an emerging pathway in the regulation of visceral pain.

Hannig G, Tchernychev B, Kurtz CB, Bryant AP, Currie MG, Silos-Santiago I.

Front Mol Neurosci. 2014 Apr 16;7:31. doi: 10.3389/fnmol.2014.00031. eCollection 2014. Review.

14.

Responders vs clinical response: a critical analysis of data from linaclotide phase 3 clinical trials in IBS-C.

Lacy BE, Lembo AJ, Macdougall JE, Shiff SJ, Kurtz CB, Currie MG, Johnston JM.

Neurogastroenterol Motil. 2014 Mar;26(3):326-33. doi: 10.1111/nmo.12264. Epub 2013 Dec 30.

15.

Effect of linaclotide on severe abdominal symptoms in patients with irritable bowel syndrome with constipation.

Rao SS, Quigley EM, Shiff SJ, Lavins BJ, Kurtz CB, MacDougall JE, Currie MG, Johnston JM.

Clin Gastroenterol Hepatol. 2014 Apr;12(4):616-23. doi: 10.1016/j.cgh.2013.09.022. Epub 2013 Sep 25.

16.

Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate.

Castro J, Harrington AM, Hughes PA, Martin CM, Ge P, Shea CM, Jin H, Jacobson S, Hannig G, Mann E, Cohen MB, MacDougall JE, Lavins BJ, Kurtz CB, Silos-Santiago I, Johnston JM, Currie MG, Blackshaw LA, Brierley SM.

Gastroenterology. 2013 Dec;145(6):1334-46.e1-11. doi: 10.1053/j.gastro.2013.08.017. Epub 2013 Aug 16.

17.

Gastrointestinal pain: unraveling a novel endogenous pathway through uroguanylin/guanylate cyclase-C/cGMP activation.

Silos-Santiago I, Hannig G, Eutamene H, Ustinova EE, Bernier SG, Ge P, Graul C, Jacobson S, Jin H, Liong E, Kessler MM, Reza T, Rivers S, Shea C, Tchernychev B, Bryant AP, Kurtz CB, Bueno L, Pezzone MA, Currie MG.

Pain. 2013 Sep;154(9):1820-30. doi: 10.1016/j.pain.2013.05.044. Epub 2013 Jun 5.

18.

An evaluation of the FDA responder endpoint for IBS-C clinical trials: analysis of data from linaclotide Phase 3 clinical trials.

Macdougall JE, Johnston JM, Lavins BJ, Nelson LM, Williams VS, Carson RT, Shiff SJ, Shi K, Kurtz CB, Baird MJ, Currie MG, Lembo AJ.

Neurogastroenterol Motil. 2013 Jun;25(6):481-6. doi: 10.1111/nmo.12089. Epub 2013 Feb 6.

PMID:
23384406
19.

Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation.

Busby RW, Kessler MM, Bartolini WP, Bryant AP, Hannig G, Higgins CS, Solinga RM, Tobin JV, Wakefield JD, Kurtz CB, Currie MG.

J Pharmacol Exp Ther. 2013 Jan;344(1):196-206. doi: 10.1124/jpet.112.199430. Epub 2012 Oct 22.

PMID:
23090647
20.

A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation.

Rao S, Lembo AJ, Shiff SJ, Lavins BJ, Currie MG, Jia XD, Shi K, MacDougall JE, Shao JZ, Eng P, Fox SM, Schneier HA, Kurtz CB, Johnston JM.

Am J Gastroenterol. 2012 Nov;107(11):1714-24; quiz p.1725.

21.

Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.

Chey WD, Lembo AJ, Lavins BJ, Shiff SJ, Kurtz CB, Currie MG, MacDougall JE, Jia XD, Shao JZ, Fitch DA, Baird MJ, Schneier HA, Johnston JM.

Am J Gastroenterol. 2012 Nov;107(11):1702-12.

PMID:
22986437
22.

Two randomized trials of linaclotide for chronic constipation.

Lembo AJ, Schneier HA, Shiff SJ, Kurtz CB, MacDougall JE, Jia XD, Shao JZ, Lavins BJ, Currie MG, Fitch DA, Jeglinski BI, Eng P, Fox SM, Johnston JM.

N Engl J Med. 2011 Aug 11;365(6):527-36. doi: 10.1056/NEJMoa1010863.

23.

Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit.

Busby RW, Bryant AP, Bartolini WP, Cordero EA, Hannig G, Kessler MM, Mahajan-Miklos S, Pierce CM, Solinga RM, Sun LJ, Tobin JV, Kurtz CB, Currie MG.

Eur J Pharmacol. 2010 Dec 15;649(1-3):328-35. doi: 10.1016/j.ejphar.2010.09.019. Epub 2010 Sep 20.

PMID:
20863829
24.

Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation.

Johnston JM, Kurtz CB, Macdougall JE, Lavins BJ, Currie MG, Fitch DA, O'Dea C, Baird M, Lembo AJ.

Gastroenterology. 2010 Dec;139(6):1877-1886.e2. doi: 10.1053/j.gastro.2010.08.041. Epub 2010 Aug 27.

PMID:
20801122
25.

Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract.

Bryant AP, Busby RW, Bartolini WP, Cordero EA, Hannig G, Kessler MM, Pierce CM, Solinga RM, Tobin JV, Mahajan-Miklos S, Cohen MB, Kurtz CB, Currie MG.

Life Sci. 2010 May 8;86(19-20):760-5. doi: 10.1016/j.lfs.2010.03.015. Epub 2010 Mar 20.

PMID:
20307554
26.

Efficacy of linaclotide for patients with chronic constipation.

Lembo AJ, Kurtz CB, Macdougall JE, Lavins BJ, Currie MG, Fitch DA, Jeglinski BI, Johnston JM.

Gastroenterology. 2010 Mar;138(3):886-95.e1. doi: 10.1053/j.gastro.2009.12.050. Epub 2010 Jan 4.

PMID:
20045700
27.

Pilot study on the effect of linaclotide in patients with chronic constipation.

Johnston JM, Kurtz CB, Drossman DA, Lembo AJ, Jeglinski BI, MacDougall JE, Antonelli SM, Currie MG.

Am J Gastroenterol. 2009 Jan;104(1):125-32. doi: 10.1038/ajg.2008.59.

PMID:
19098860
28.

Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome.

Andresen V, Camilleri M, Busciglio IA, Grudell A, Burton D, McKinzie S, Foxx-Orenstein A, Kurtz CB, Sharma V, Johnston JM, Currie MG, Zinsmeister AR.

Gastroenterology. 2007 Sep;133(3):761-8. Epub 2007 Jul 3.

PMID:
17854590
29.

Toxin binding of tolevamer, a polyanionic drug that protects against antibiotic-associated diarrhea.

Braunlin W, Xu Q, Hook P, Fitzpatrick R, Klinger JD, Burrier R, Kurtz CB.

Biophys J. 2004 Jul;87(1):534-9.

30.

GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis.

Kurtz CB, Cannon EP, Brezzani A, Pitruzzello M, Dinardo C, Rinard E, Acheson DW, Fitzpatrick R, Kelly P, Shackett K, Papoulis AT, Goddard PJ, Barker RH Jr, Palace GP, Klinger JD.

Antimicrob Agents Chemother. 2001 Aug;45(8):2340-7.

31.
32.

Loss of human CR1- and murine Crry-like exons in human CR2 transcripts due to CR2 gene mutations.

Holguin MH, Kurtz CB, Parker CJ, Weis JJ, Weis JH.

J Immunol. 1990 Sep 15;145(6):1776-81.

PMID:
2144008
34.
35.

Genetic organization of complement receptor-related genes in the mouse.

Kingsmore SF, Vik DP, Kurtz CB, Leroy P, Tack BF, Weis JH, Seldin MF.

J Exp Med. 1989 Apr 1;169(4):1479-84.

36.

The murine complement receptor gene family. Analysis of mCRY gene products and their homology to human CR1.

Paul MS, Aegerter M, O'Brien SE, Kurtz CB, Weis JH.

J Immunol. 1989 Jan 15;142(2):582-9.

PMID:
2911011
37.

Effects of products of activated leukocytes (lymphokines and monokines) on the growth of malignant trophoblast cells in vitro.

Berkowitz RS, Hill JA, Kurtz CB, Anderson DJ.

Am J Obstet Gynecol. 1988 Jan;158(1):199-203.

PMID:
2447775

Supplemental Content

Loading ...
Support Center